This below article is posted on JNJ news. While not directly related to Amyris, this is the intention of the new partnership with JNJ. To create biosynthetic drugs then bring them to market.
Amgen Biosimilar Gets Thumbs-Up From FDA Panel
Source: Dow Jones News
The second-biggest selling drug in the world could get some cheaper competition in the U.S., after a federal panel endorsed an alternative version of the pricey medication used to treat rheumatoid arthritis and other inflammatory diseases.
A panel of Food and Drug Administration advisers voted unanimously in favor of Amgen Inc.'s version of AbbVie Inc.'s Humira, a biotech drug that, according to IMS Health, raked in nearly $15 billion last year. While not binding, the recommendation likely paves the way for FDA approval of the knockoff drug.
For years, biotech drugs faced no competition because there was no regulatory way to approve copycat versions, even after patents had expired. If approved, Amgen's drug would join a new wave of so-called biosimilars, which have the potential to generate billions in savings for U.S. insurers, doctors and patients.
